Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Leases (2019 - 2025)

CytomX Therapeutics filings provide 7 years of Current Leases readings, the most recent being $4.2 million for Q4 2025.

  • On a quarterly basis, Current Leases fell 17.59% to $4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 17.59% decrease, with the full-year FY2025 number at $4.2 million, down 17.59% from a year prior.
  • Current Leases hit $4.2 million in Q4 2025 for CytomX Therapeutics, down from $5.6 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $5.6 million in Q3 2025 to a low of $3.6 million in Q4 2021.
  • Median Current Leases over the past 5 years was $4.5 million (2023), compared with a mean of $4.5 million.
  • Biggest five-year swings in Current Leases: increased 12.82% in 2022 and later fell 17.59% in 2025.
  • CytomX Therapeutics' Current Leases stood at $3.6 million in 2021, then increased by 12.82% to $4.1 million in 2022, then grew by 12.42% to $4.6 million in 2023, then rose by 12.12% to $5.1 million in 2024, then decreased by 17.59% to $4.2 million in 2025.
  • The last three reported values for Current Leases were $4.2 million (Q4 2025), $5.6 million (Q3 2025), and $5.4 million (Q2 2025) per Business Quant data.